Skip to main content
All lobbying filings

Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings filed a Q1 report for Laboratory Corporation of America Holdings on April 13, 2026.

Lobbying for Laboratory Corporation of America Holdings

As filed: LABORATORY CORPORATION OF AMERICA HOLDINGS for LABORATORY CORPORATION OF AMERICA HOLDINGS.

All filings by Laboratory Corporation of America Holdings · Everything Laboratory Corporation of America Holdings has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 13, 2026
Expenses
$890,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
North Carolina

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6226 of H.R. 7148, the Consolidated Appropriations Act, 2026, Pub. L. 119-75, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 6280/S. 3607, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; S. 3315, the Health Care Cybersecurity and Resiliency Act, provisions relating to cybersecurity; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

 Bills named in this filing 8
  • H.R. 5269
    RESULTS Act
  • S. 2761
    RESULTS Act
  • H.R. 7148
    Consolidated Appropriations Act, 2026
  • H.R. 6280
    Access to Genetic Counselor Services Act of 2025
  • S. 3607
    Access to Genetic Counselor Services Act of 2026
  • H.R. 5582
    Patients Deserve Price Tags Act
  • S. 2355
    Patients Deserve Price Tags Act
  • S. 3315
    Health Care Cybersecurity and Resiliency Act of 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem